Thread by @sbarnettARK

JPM Healthcare Daily Roundup #JPM2021

The first day of the conference hasn't disappointed, especially if you're a fan of talking cubes. What is this mysterious object and what sorcery is inside?

See disclosures at the end.

The Tempus One, meant to be carried in a doctor's coat or sat at the bedside, is a physical manifestation of @TempusLabs' genomic and phenotypic data-lake. Oncologists can ask One all sorts of questions regarding their patients, though I'm unsure if it'll (...)

(...) just reflex you to a computer after a sufficiently difficult question. I'm sure we'll learn more soon. Has this sort of form-factor been tried before?

I'm just hoping it has adjustable humor/honesty settings like TARS from Interstellar.

Moving right along.

@10xGenomics inundated us w/ new product launches including:

CellPlex - a reagent/software package for sample multiplexing (four samples/channel, up to 60% cost reduction if fully loaded).

Low Throughput - Have 1,000 cells you'd like to run in a pilot study? You're in luck!

Fixed RNA Kit - point-of-collection tissue fixation, compatible w/ targeted or transcriptome workflows

Chromium X (that's an X, not a 10!) - a massive 1-million cell behemoth run on Next GEM, likely for the translational folks?

But, what about spatial #genomics? Read on.

The Visium FFPE Kit enables targeted/#transcriptome work to be run on FFPE samples w/ near fresh-frozen levels of gene sensitivity.

Have archived FFPE tissue on non-Visium slides? No worries, the Visium CytAssist can convert standard slides to Visium-compatible slides.

Coming in 2022, Visium evolves into Visium HD, with a resolution increase from 4X to 1,500X.

Interestingly, no real commentary on 'in situ' imaging. I guess no one wants to be the first to lay out their full range of specs (I eagerly await @agbt).

Next!

@GuardantHealth gave me a shock that it plans to move into tissue (!) profiling. I suppose this was an eventuality given that tissue isn't going anywhere - clinician habit, tissue/liquid concordance concerns, etc.

I don't think this will morph into a tumor-informed liquid test.

Finally, we heard about Guardant Reveal, a liquid-only #MRD assay for colorectal cancer (initially), the result of the ongoing Lunar 1 program.

It seems there's no escaping that adding #epigenetic (and fragmentomic) data overtop #ctDNA boosts detection sensitivity.

Onward.

I missed the Seer talk, but took note that they gained non-exclusive rights to commercialize some of @thermofisher's and @bruker's mass spec portfolio.

#Proteomics, super-resolution optics, & cryoEM all seem like cool places to be right now, though earlier than #NGS.

@illumina's announcements are always fun, though some of my predictions didn't come true this year.

I was mulling a NovaSeq Dx launch, a clear $100-genome roadmap, or a small tool's acquisition to bolster long-read-esque capabilities. What we got was the following (...)

- A 2022 NovaSeq Dx launch window
- A lower-throughput (P1) flow cell for NextSeq 2000 (which is one of the prettiest sequencers I ever did see)
- A metric TON of IVD collaborations for TruSight and others (read: GRAIL MRD)
- A robust tool for backend multi-omics processing (ICA)

@GrailBio moved up its timeline to launch Galleri to 2Q 2021, possibly ahead of the acquisition and far ahead of any clinical utility data?

I'm unsure what the huge rush is, but maybe others have some ideas?

I'm still working my way through @TwistBioscience , @AdaptiveBiotech, and a few others. I'll return to keep adding little sprinkles here and there.

In the meantime, go OSU!

bit.do/eyRo8